Abstract Background Single molecule array (Simoa) technology enables the detection of Alzheimer’s disease (AD) neuropathology in blood. This study compared cross‐sectional biomarker profiles for participants from the New Zealand‐Dementia Prevention Research Clinics (NZ‐DPRCs) who spanned the continuum from healthy older adults to a clinical diagnosis of AD. Method NZ‐DPRC participants were clinically classified as cognitively unimpaired adults (CU, n=34), subjective cognitive decline (SCD, n=65), non‐amnestic mild…